Welcome to our dedicated page for Tempest Therapeutics SEC filings (Ticker: TPST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tempest Therapeutics, Inc. (NASDAQ: TPST) SEC filings page on Stock Titan provides investors with direct access to the company’s regulatory disclosures, along with AI-assisted context. Tempest is a clinical-stage biotechnology company headquartered in Brisbane, California, developing small molecule and cell-based therapeutics with tumor-targeted and immune-mediated mechanisms to fight cancer.
Through this page, users can review Tempest’s Form 8-K current reports, which the company uses to announce material events such as equity financings, asset purchase agreements, and leadership changes. For example, Tempest has filed 8-Ks describing registered direct offerings of common stock and concurrent private placements of warrants, as well as an asset purchase agreement to acquire dual-targeting CAR T-cell therapy programs from Factor Bioscience affiliates.
Investors can also use this section to locate Tempest’s periodic reports, such as Forms 10-Q and 10-K, which include detailed financial statements, risk factor discussions, and management’s analysis of its clinical-stage oncology pipeline and capital resources. These filings complement the company’s press releases on quarterly financial results and business updates.
Stock Titan enhances Tempest’s SEC filings with AI-powered summaries that highlight key terms, financing structures, and transaction conditions, helping readers quickly understand complex documents without replacing the full text. The platform also surfaces information on equity issuances, warrant terms, and other securities-related disclosures reported under unregistered sales of equity securities. Real-time updates from the EDGAR system ensure that new TPST filings, including future 10-K, 10-Q, and 8-K reports, appear promptly, allowing investors to track Tempest’s regulatory history and ongoing corporate developments in one place.
Tempest Therapeutics reported promising interim data for TPST-2003, a CD19/BCMA dual-targeting CAR-T therapy for relapsed/refractory multiple myeloma from the ongoing Phase 1/2a REDEEM-1 trial and a prior IIT.
As of January 31, 2026, 36 patients had received TPST-2003. All six efficacy-evaluable patients in REDEEM-1 achieved complete responses, and among 25 evaluable patients with measurable disease across both studies, the overall response rate was 100% (25/25). Patients in REDEEM-1 had a median of four prior lines of therapy, underscoring the heavily pretreated population. A favorable safety profile was observed across dose levels.
Based on these results, Tempest plans to accelerate development, submit a U.S. IND, and, subject to clearance, initiate a U.S. registrational study of TPST-2003 in 2026, while also exploring additional indications such as large B-cell lymphoma.
Tempest Therapeutics filed an 8-K to share a new investor presentation outlining its oncology pipeline and clinical data. The deck highlights TPST-2003, a dual CD19/BCMA CAR-T for relapsed/refractory multiple myeloma with extramedullary disease, which showed a 100% hematologic objective response rate in 18 patients and 75.3% 12‑month progression-free survival, with manageable CRS and ICANS rates.
The presentation also details amezalpat (TPST‑1120), a first-in-class PPARα antagonist, which in a randomized Phase 1b/2 hepatocellular carcinoma study improved median overall survival to 21 months versus 15 months for atezolizumab plus bevacizumab alone, with a hazard ratio of 0.65 and higher confirmed response rates, while maintaining a similar safety profile. Tempest has regulatory alignment with FDA, EMA and China’s NMPA on a pivotal Phase 3 design and notes orphan drug and Fast Track designations for amezalpat. Additional programs include TPST‑1495 moving into an NCI-funded Phase 2 trial in familial adenomatous polyposis and multiple CAR‑T collaborations with Novatim, many of which are partner-funded.
Tempest Therapeutics CEO Matthew Angel has filed a Schedule 13D reporting a large ownership stake in the company. He beneficially owns 4,837,070 shares of common stock, representing 35.9% of Tempest’s outstanding shares immediately after an asset purchase transaction involving Erigen LLC and Factor Bioscience.
The shares were issued to Erigen as consideration for certain assets and then allocated to its equityholders, including Angel, who invested personal funds to buy his Erigen interest. Angel holds sole voting and dispositive power over all reported shares and acquired them for investment purposes, with the possibility of additional equity awards or sales over time.
The asset purchase agreement requires Tempest to file a resale registration statement for the shares issued to Erigen, and a lock-up agreement restricts transfers of 50% of Erigen’s Tempest stock for 180 days after closing. Angel, now Chief Executive Officer, President and director, states he currently has no specific plans for corporate control or structural changes beyond these disclosed arrangements.
Tempest Therapeutics, Inc. CEO, President and director Matthew Angel, also a 10% owner, reported a grant of employee stock options on February 4, 2026. He received options to purchase 269,621 shares of common stock at an exercise price of $2.38 per share, expiring on February 3, 2036.
According to the vesting schedule, 25% of the underlying shares will vest on February 4, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter, subject to his continued service. Following this award, he beneficially owns 269,621 derivative securities directly.
Tempest Therapeutics CEO and President Matthew Angel, who also serves as a director and 10% owner of Tempest Therapeutics, Inc., filed an initial Form 3. The filing reports 8,268,495 shares of common stock held indirectly through Erigen LLC.
The shares are owned by Erigen LLC, where Angel is a member, and he disclaims beneficial ownership of these securities except for his proportionate pecuniary interest. This filing establishes his indirect ownership position under Section 16 reporting rules.
Tempest Therapeutics completed an asset acquisition from Erigen and Factor Bioscience, issuing 8,268,495 shares of common stock as consideration for four CAR T-cell therapy programs. Immediately afterward, prior equityholders owned about 38.7% of the company and Erigen held about 61.3%.
The company also executed a one-time warrant distribution, issuing 6,784,989 warrants, each allowing the purchase of one share of common stock at $18.48 per share in cash until February 3, 2031, subject to an effective registration statement. As of immediately after the share issuance, 13,481,070 common shares were outstanding.
Governance shifted as Geoff Nichol resigned from the board, Michael Raab was succeeded as board chair by Stephen Brady, and Brady resigned as President and CEO. Matthew (Matt) Angel, Ph.D. became President, CEO and a Class I director under a new employment agreement that includes equity awards and severance protections.
Tempest Therapeutics director Ronit Simantov received a stock option grant for 1,230 shares on January 27, 2026. The option has an exercise price of $2.94 per share and was granted at no cost. It will vest in full on the earlier of January 27, 2027, or the company’s 2026 annual stockholder meeting, provided Simantov continues serving through that date.
Tempest Therapeutics director receives stock option grant. Director Michael Raab was granted a stock option to purchase 1,230 shares of Tempest Therapeutics, Inc. common stock at an exercise price of
The option vests in full on the earlier of
Tempest Therapeutics director Nichol Geoffrey received a grant of stock options on January 27, 2026. The award covers 1,230 options to buy Tempest common stock at an exercise price of $2.94 per share, all held directly.
These options will vest in full on the earlier of January 27, 2027, or the day of Tempest’s 2026 annual stockholder meeting, if Geoffrey continues to serve through that date. Following this grant, he beneficially owns 1,230 derivative securities linked to Tempest shares.
Tempest Therapeutics director Christine A. Pellizzari reported a new stock option grant. On January 27, 2026, she was awarded an option to buy 1,230 shares of Tempest Therapeutics common stock at an exercise price of $2.94 per share, held directly.
The option vests in full on the earlier of January 27, 2027 or the day of Tempest Therapeutics' 2026 annual stockholder meeting, as long as she continues serving through that date. The option expires on January 26, 2036, and represents 1,230 derivative securities beneficially owned following the grant.